Tisch MSRCNY and Dr. Violaine Harris have been featured in an article in Managed Healthcare Executive about the preliminary analysis of results from our FDA-approved stem cell treatment study. The Q&A highlights the impact of our stem cell research, in particular the potential of our biomarker...
Last week our researchers and physicians discussed a paper about the identification of anti-oligodendrocyte antibodies and their implications in MSdisease pathology. MSis an autoimmune disease characterized by damage to the Central Nervous System (CNS), specifically to myelin sheaths and...
The paper shows that MS patients receiving anti-CD20 therapy saw strong T-cell activation in response to receiving the COVID-19 vaccination, even in conditions of deficient antibody production. Furthermore, our research found no difference in patients’ T-cell response regardless of form of the...